Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1

Abstract (PubMed)

An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. In this phase 2b, open-label study with 14 treatment subgroups, 571 patients without cirrhosis were randomly assigned to regimens of ABT-450/r combined with ABT-267 or ABT-333 or both, for 8, 12, or 24 weeks, with or without ribavirin. The primary end point was sustained virologic response at 24 weeks (SVR24). SVR24 rates ranged from 83% to 99% across subgroups in previously untreated patients and from 47% to 93% in prior non-responders.